Brenna Gerdeman
Primary Care · Columbus, OHNPI 1700373420
Payments from drug & device makers
Across 143 payments — averaging $11.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$637
- Biohaven Pharmaceuticals, Inc.$165
- Redhill Biopharma Inc.$151
- Lilly USA, LLC$96
- Daiichi Sankyo Inc.$87
- Amarin Pharma, Inc.$84
- plus $378 from 9 others
What the payments were for
- Food & beverage$1,55797%
- Education$423%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 73 | $637 |
| Biohaven Pharmaceuticals, Inc. | 16 | $165 |
| Redhill Biopharma Inc. | 12 | $151 |
| Lilly USA, LLC | 7 | $96 |
| Daiichi Sankyo Inc. | 6 | $87 |
| Amarin Pharma, Inc. | 5 | $84 |
| AstraZeneca | 5 | $63 |
| Hikma Pharmaceuticals USA | 3 | $62 |
| Jazz Pharmaceuticals Inc. | 4 | $58 |
| Boehringer Ingelheim | 3 | $45 |
| Alkermes, Inc. | 2 | $45 |
| Indivior Inc. | 2 | $29 |
| Amgen | 2 | $27 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
How this compares
$1,599 in reported general payments places this provider in the 80th percentile of 321 primary care providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 167 | $16,412 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $62 | $16,412167 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 321 primary care providers in Ohio.
Other primary care in Columbus
- Joseph PriceColumbus$6K
- Madison WaltersColumbus$6K
- Jordyn WilsonColumbus$4K
- Christopher BaranColumbus$3K
- Macy BaileyColumbus$2K
- Stephanie HoheiselColumbus$2K
- Sheila CaniniColumbus$2K
- Sarah AndersonColumbus$2K
- Shireen ShattiColumbus$2K
- Adine EdwardsSpringfield$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.